Perceived Health After Hospitalization for COVID-19 (PRO-COVID)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Dijon, France
- Chu Dijon Bourogne
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patient
- Patient with a diagnosis of COVID-19 confirmed by PCR and/or CT scan
- Patient hospitalized in a short stay unit (excluding intensive care and rehabilitation) for a COVID-19 infection
- Patient providing oral consent to participate in the study
- Patient able to understand and answer the questionnaires used
- Patient able to answer the questions on an electronic device and to receive requests by email and/or SMS
- Patient who has electronic equipment at home and an Internet subscription allowing him/her to answer the questionnaires online
Exclusion Criteria:
- Patient under guardianship, curatorship or a measure of judicial safeguard
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
COVID-19 Patient
Patient discharged from a conventional short-stay hospitalization unit.
|
SF-12, GHQ-12 and HAQ
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to PASS and CID in patients discharged from conventional hospitalization for COVID-19 disease
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
|
The value of perceived health scores in patients who achieved PASS and MCII
Time Frame: Through study completion, an average of 6 months
|
Through study completion, an average of 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DEVILLIERS AOIc 2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.